NCT05938725View on ClinicalTrials.gov

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Lupus NephritisLupus Nephritis - World Health Organization (WHO) Class IIILupus Nephritis - WHO Class IV
Interventions
BIOLOGICAL

KYV-101 anti-CD19 CAR-T cell therapy

KYV-101 anti-CD19 CAR-T cell therapy

DRUG

Standard lymphodepletion regimen

Standard lymphodepletion regimen

Trial Locations (6)

11021

RECRUITING

Northwell Health, Great Neck

19104

RECRUITING

University of Pennsylvania, Philadelphia

43210

RECRUITING

Ohio State University Wexner Medical Center, Columbus

80045

RECRUITING

University of Colorado, Denver

94305

RECRUITING

Stanford University Medical Center, Palo Alto

01655

RECRUITING

University of Massachusetts Worcester, Worcester

Sponsors
All Listed Sponsors
lead

Kyverna Therapeutics

INDUSTRY

NCT05938725 - KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | Biotech Hunter | Biotech Hunter